about
Prognostic biomarkers in acute coronary syndromeCardiopulmonary laboratory biomarkers in the evaluation of acute dyspneaInvestigation into the feasibility of thioditaloside as a novel scaffold for galectin-3-specific inhibitorsCan biomarkers help to diagnose early heart failure with preserved ejection fraction?Galectin 3 and incident atrial fibrillation in the community.Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure.Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure.Phidippides cardiomyopathy: a review and case illustration.Galectin-3 and left ventricular reverse remodelling after surgical mitral valve repair.Systematic analysis of blood cell transcriptome in end-stage chronic respiratory diseases.A genome-wide association study of circulating galectin-3Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy.Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary studyEvolution of biomarker guided therapy for heart failure: current concepts and trial evidence.Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablationTranscriptional analysis of the endothelial response to diabetes reveals a role for galectin-3.Analysis of the intracellular role of galectins in cell growth and apoptosis.Plasma galectin 3 and heart failure risk in the Physicians' Health Study.Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices.Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart FailureElevated galectin-3 precedes the development of CKDGalectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation.The Indian Consensus Document on cardiac biomarker.Novel biomarkers in human terminal heart failure and under mechanical circulatory support.Pathophysiological role of inflammatory molecules in paediatric ischaemic brain injury.The effect of galectins on leukocyte trafficking in inflammation: sweet or sour?Neutrophil gelatinase-associated lipocalin as diagnostic and prognostic tool for cardiovascular disease and heart failure.The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.Investigational drugs targeting cardiac fibrosis.Galectin-3: a modifiable risk factor in heart failure.Markers of left ventricular decompensation in aortic stenosis.Long-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes.Ischemic postconditioning alters the gene expression pattern of the ischemic heart.The role of cardiac biochemical markers in aortic stenosis.From Inflammation to Fibrosis-Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities.Protective Effect of Adansonia digitata against Isoproterenol-Induced Myocardial Injury in Rats.Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease.
P2860
Q26738521-A29CC280-0898-4437-A04F-2BF6E6E5DD90Q26745756-81B41555-4AC6-4682-BC51-FE09C86C1C90Q27685236-C7C8DD04-68BA-44F8-A830-D3F1DDB72AA0Q28087822-7601B34C-38B1-441D-99D7-3E02C59376CDQ33555143-D5E54516-5B14-41FB-AAF6-5F6E74E7E2C8Q33912126-4311E3B4-82FA-46F7-AAB7-AACEE986DC98Q34102031-C9F1BD27-F145-4A95-A28E-D067065701B1Q34245017-681DA940-4296-4F4C-9DE3-69D48253FA5FQ34338521-F51D5FD8-74FD-49D7-8651-CB03FB49C26CQ34373840-2DA1A4E6-1F20-4232-94D8-3BEBED91B618Q34443077-0A0EBD6C-59AD-4FF2-9FAB-BED2EF64E2A5Q34524341-1C395C36-435C-414B-BD17-5767BF652191Q34528187-5A9A7B85-F9BD-47C5-A43A-CF6BA57CC559Q35025805-468AE926-8D95-4604-9FF5-15137364E89EQ35139977-E4C714FD-2EB7-438B-8B97-CA3BAB78B649Q35286926-6E6E656D-DEF7-485C-8A33-6E88C67A3B46Q35432573-B041807D-021F-4658-A486-D48ECC728AA3Q35553234-D7329617-E9A8-41E4-8020-B7A9C7C5B802Q36041236-DCAC7741-9CA3-4CDC-9BF2-59234FD1045EQ36283028-CD967AE7-2198-41B0-B638-C0B270D3E77AQ36297961-8043D422-D95F-49CA-96C0-2FF58775C082Q36439679-08EEE6F8-4EB7-448C-B609-A46C0D184CABQ36757833-EF1DCCC6-EED9-49BA-A18E-3BFD836B08EEQ37119904-463562A5-5BE4-4C19-ACE9-7C9952C33E91Q37581717-E3BA7B78-7245-412A-8C73-FE098C5BD572Q37624484-B99E29A8-C67E-4A22-BCF1-A2D477E90A72Q37894731-B8391E85-8F45-4EB0-A366-A3A61D70A33CQ37976090-25796DF7-EE54-4BF1-8BB3-9D415CA97EC3Q37976826-24E72ABA-79E0-48C6-AB9A-046264D181B1Q38093260-9D630563-B320-4EB6-8524-9D15D6E01CA2Q38154222-A68247AE-4669-4BB1-822C-A75382E0FEEAQ38161896-65479DEA-A78F-4703-83A2-C042F7C3D68BQ38208784-81124628-F347-445A-B2C2-60DE36D65E62Q38215381-C85C0F2B-23FA-4943-9F81-C704023E865FQ38426618-0035644E-DE13-4C93-8789-0C6D2295113FQ38481119-0B4074BA-F85D-4E99-943C-1858BB8D74EEQ38743657-597E57D6-3F66-418F-8DFB-D0A5D4DBA6D1Q39434474-73DDB523-4069-48CC-9883-71B82ACE8198Q39970169-DF9D0F52-8E6C-4CBF-82CB-288BF480E108Q40060474-54BCE304-A4AC-4CCE-8A67-65BFBFA6050D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Galectin-3 in cardiac remodeling and heart failure.
@en
Galectin-3 in cardiac remodeling and heart failure.
@nl
type
label
Galectin-3 in cardiac remodeling and heart failure.
@en
Galectin-3 in cardiac remodeling and heart failure.
@nl
prefLabel
Galectin-3 in cardiac remodeling and heart failure.
@en
Galectin-3 in cardiac remodeling and heart failure.
@nl
P2860
P921
P1476
Galectin-3 in cardiac remodeling and heart failure.
@en
P2093
Rudolf A de Boer
P2860
P2888
P356
10.1007/S11897-010-0004-X
P577
2010-03-01T00:00:00Z